Shots: The partial hold on clinical study for intrathecal administration of AVXS-101 follows the findings of the pre-clinical study demonstrated dorsal root ganglia (DRG) mononuclear cell inflammation accompanied by neuronal […]readmore
Tags : onasemnogene abeparvovec-xioi
Regulatory
Novartis’ Zolgensma (onasemnogene abeparvovec-xioi) Receives FDA’s Approval for Spinal Muscular
Shots: The approval is based on ongoing P-III STR1VE & completed P-I START study result assessing Zolgensma (IV) in 21 & 15 patients with SMA and bi-allelic mutation in the […]readmore
Shots: The P-III STR1VE study involves assessing of Zolgensma in 22 patients with SMA Type1 + one or two copies of the SMN2 backup gene + bi-allelic SMN1 gene deletion […]readmore